For research use only. Not for therapeutic Use.
SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response[1]. SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity[2].
| Catalog Number | I009525 |
| CAS Number | 226907-52-4 |
| Synonyms | 6-amino-9-benzyl-2-(2-methoxyethoxy)-7H-purin-8-one |
| Molecular Formula | C15H17N5O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H17N5O3/c1-22-7-8-23-14-18-12(16)11-13(19-14)20(15(21)17-11)9-10-5-3-2-4-6-10/h2-6H,7-9H2,1H3,(H,17,21)(H2,16,18,19) |
| InChIKey | YYCDGEZXHXHLGW-UHFFFAOYSA-N |
| SMILES | COCCOC1=NC(=C2C(=N1)N(C(=O)N2)CC3=CC=CC=C3)N |
| Reference | [1]. Dharmapuri S, et al. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther. 2009;16(5):462-472. [2]. Lee J, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A. 2006;103(6):1828-1833. |
